A new weight loss pill has been shown to help slimmers lose around 12 per cent of their body weight over 72 weeks.
Alongside its weight loss benefits, the oral pill has been shown to reduce blood pressure and cholesterol levels.
The oral drug, called orforglipron, works by making the consumer feel fuller and suppressing the appetite.
**ARE YOU READING THIS ON OUR APP? DOWNLOAD NOW FOR THE BEST GB NEWS EXPERIENCE**
Alongside weight loss, orforglipron's benefits include reduced blood pressure and cholesterol
|GETTY
Although it is currently unavailable for public consumption, the trial findings are due to be presented to the European Association for the Study of Diabetes annual meeting by its manufacturer, Eli Lilly.
Currently undergoing preparations to submit the drug for licensing by the end of 2025, the manufacturer intends to make the launch global "to address this urgent public health need".
Initial findings of the major trial indicate that individuals who consumed the highest dosage lost almost two stone over 16 months.
However, around 10 per cent stopped administering the drug due to its side effects, such as nausea, diarrhoea, and vomiting.
LATEST DEVELOPMENTS
"Obesity is one of the most pressing global health challenges of our time, driving global chronic disease burden and impacting more than one billion people worldwide," executive vice president and president of Lilly Cardiometabolic Health Kenneth Custer said.
"With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments.
"With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need."
The manufacturer hopes to launch the drug by the end of the year
|GETTY
The non-injectable weight loss pill will be rivalled by its pharmaceutical competitor Novo Nordisk's oral semaglutide (marketed as Wegovy), which has been submitted for approval by US agencies.
If rolled out, orforglipron will provide a new alternative to weight loss solutions currently available.
However, it's worth noting that the oral pill may be considerably less effective than its injectable counterparts.
While those who took orforglipron dropped 12 per cent of their weight, individuals taking a weekly injection of Mounjaro have experienced an approximate drop of 22 per cent.